Comparative Pharmacology
Head-to-head clinical analysis: GOMEKLI versus RIOMET ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GOMEKLI versus RIOMET ER.
GOMEKLI vs RIOMET ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-3 adrenergic receptor agonist; increases bladder capacity by relaxing the detrusor smooth muscle during urine storage.
Biguanide that decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
5 mg orally once daily.
Oral, 500 mg once daily, increase by 500 mg weekly to maximum 2000 mg once daily.
None Documented
None Documented
The terminal elimination half-life of GOMEKLI is approximately 4 hours in healthy adults. In patients with renal impairment (CrCl <30 mL/min), the half-life is prolonged to about 8 hours, necessitating dose adjustment.
Terminal elimination half-life is approximately 6.2 hours in patients with normal renal function; prolonged to up to 17.6 hours in renal impairment (eGFR <30 mL/min).
GOMEKLI is primarily eliminated via the kidneys. Renal excretion accounts for approximately 70% of the administered dose, with about 90% of that as unchanged drug. Biliary/fecal excretion accounts for the remaining 30%, mainly as metabolites. Less than 1% is excreted in feces as unchanged drug.
Renal elimination of unchanged drug accounts for approximately 90% of an absorbed dose; fecal excretion is minimal (<5%).
Category C
Category C
Biguanide Antidiabetic
Biguanide Antidiabetic